BioSpace Med is touting a small study of its low-dose imaging workstation showing that the EOS 2D/3D device produces better image quality and significantly reduces patients’ radiation exposure.
The study, published in the peer-reviewed journal Spine, showed "significantly better" image quality compared to a computed radiography X-ray scan while "substantially reducing (a) patient’s (radiation) dose exposure" by up to 89 percent compared to CR imaging.
The 50-patient trial tracked 39 girls and 11 boys of an average age of 14.8 years for spine deformity. All patients received CR and EOS exams and were measured for skin dose radiation. The results showed 97.2 percent of the exams were of equal or better quality when the EOS system was used. Dose reduction factors ranked from 2.9 (neck) to 9.2 (iliac crest), according to a press release.
Earlier this week BioSpace Med pulled in $18 million it plans to use to increase its footprint in North America and Europe. The Paris-based company, which houses its U.S. headquarters in Cambridge, Mass., said it will use the infusion to expand market penetration for the EOS device.
The system won 510(k) clearance from the Food & Drug Administration in March for children with spinal problems. The device, which consists of a scanner and a three-dimensional bone-modeling program, can capture head-to-toe images of patients in a standing, weight-bearing position, which can help orthopedic surgeons determine balance, posture and the position of each vertebra. The company says the workstation enables better assessments for surgical planning.
The imaging device emits much smaller amounts of radiation than conventional x-rays and nearly 1,000 times less than a computed tomography scan, which is advantageous for children who suffer from scoliosis or other types of musculoskeletal disorders that require regular X-rays.